BMS-986298 clinical trials
BMS-986298 is named as an intervention in 2 current clinical trials in our USA, France, Italy, Poland, Brazil, Ireland, Spain, Czechia, Portugal, Turkey and Mexico registers. None are recruiting at the moment. The most common phase is Phase 3. The lead sponsor is Bristol-Myers Squibb. The most-studied condition is Clear Cell Renal Cell Carcinoma.
Patient leaflets for BMS-986298
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of BMS-986298
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread
NCT04810078 · Clear Cell Renal Cell Carcinoma
|
Phase 3 | Active, closed | Bristol-Myers Squibb | Ireland, USA, France, Spain, Italy, Poland, Czechia, Portugal, Turkey, Brazil, Mexico |
|
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
NCT06946797 · Non-Small Cell Lung Cancer
|
Phase 2 | Active, closed | Bristol-Myers Squibb | USA, France, Italy, Poland, Brazil |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with BMS-986298
2 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Bristol-Myers Squibb | 2 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about BMS-986298 trials
How many clinical trials are testing BMS-986298?
2 current trials in our USA, France, Italy, Poland, Brazil, Ireland, Spain, Czechia, Portugal, Turkey and Mexico registers name BMS-986298 (also registered as Nivolumab and rHuPH20) as a drug or biological intervention, as of the registry sync on 22 October 2026. Completed and withdrawn studies are not counted.
Are BMS-986298 trials recruiting patients?
Not at the moment. None of the 2 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Who sponsors BMS-986298 clinical trials?
The lead sponsor is Bristol-Myers Squibb. The number in brackets is how many trials each organisation leads.
Are there BMS-986298 clinical trials in Ireland?
Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how BMS-986298 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how BMS-986298 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists BMS-986298 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 22 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.